[68Ga]Ga-P16-093与[68Ga]Ga-PSMA-617在复发性前列腺癌动态PET/CT中的头对头比较
本研究前瞻性纳入20例复发性前列腺癌患者,在同一组患者中连续两天分别行[68Ga]Ga-P16-093和[68Ga]Ga-PSMA-617动态PET/CT,比较早期动态器官分布与肿瘤检测能力。结果显示[68Ga]Ga-P16-093在4分钟时肿瘤摄取更高、血池滞留更少,60分钟时膀胱累积更低,且肿瘤检测能力更优。
要点
- 20例复发性前列腺癌患者同一组内头对头比较两种示踪剂。
- [68Ga]Ga-P16-093在4分钟肿瘤SUVmax更高且血池本底更低。
- [68Ga]Ga-P16-093肿瘤检测能力优于[68Ga]Ga-PSMA-617(366 vs. 321,P=0.009)。
核心结论
- 在复发性前列腺癌患者中,[68Ga]Ga-P16-093较[68Ga]Ga-PSMA-617具有更高的肿瘤摄取、更高的瘤血比和检测能力,且血池与膀胱累积更少。
研究设计与样本
- 前瞻性研究,纳入20例复发性前列腺癌患者,连续两天分别静脉注射148-185 MBq(4-5 mCi)[68Ga]Ga-P16-093和[68Ga]Ga-PSMA-617后行60分钟动态PET/CT。
- 动态PET/CT在9个时间点采集:4、7、10、13、16分钟各30秒/床位;20、30、45分钟各1分钟/床位;60分钟2分钟/床位。
- 采用标准化摄取值进行半定量比较。
主要发现
- [68Ga]Ga-P16-093在4分钟肿瘤SUVmax显著高于[68Ga]Ga-PSMA-617(7.88±5.26 vs. 6.01±3.88,P<0.001)。
- [68Ga]Ga-P16-093在4分钟血池SUVmean显著低于[68Ga]Ga-PSMA-617(5.12±1.16 vs. 6.14±0.98,P<0.001)。
- [68Ga]Ga-P16-093在60分钟膀胱SUVmean显著低于[68Ga]Ga-PSMA-617(31.33±27.47 vs. 48.74±34.01,P=0.042)。
- [68Ga]Ga-P16-093在腮腺、肝脏、脾脏和肾脏的摄取也显著高于[68Ga]Ga-PSMA-617。
- [68Ga]Ga-P16-093的肿瘤检测能力优于[68Ga]Ga-PSMA-617(366 vs. 321,P=0.009)。
关键数值与推荐
- 注射剂量:148-185 MBq(4-5 mCi)。
- 动态采集时间点:4、7、10、13、16、20、30、45、60分钟。
- 肿瘤检测能力:366 vs. 321(P=0.009)。
- 4分钟肿瘤SUVmax:7.88±5.26 vs. 6.01±3.88(P<0.001)。
- 4分钟血池SUVmean:5.12±1.16 vs. 6.14±0.98(P<0.001)。
临床怎么用
- 在复发性前列腺癌的动态PET/CT评估中,[68Ga]Ga-P16-093可提供更高的早期肿瘤摄取和更低的血池本底,有助于提高病灶检出。
- 其较低的膀胱累积可能有利于盆腔病灶的观察。
- 本研究为前瞻性同一组患者头对头比较,结果支持[68Ga]Ga-P16-093作为潜在替代示踪剂,但需进一步验证。
局限性
- 样本量较小(20例)。
- 试验为回顾性注册(NCT04796467,2021年3月12日注册)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study was prospectively designed to evaluate the early dynamic organ distribution and tumor detection capability of [68 Ga]Ga-P16-093, which was compared with [68 Ga]Ga-PSMA-617 in the same group of recurrent prostate cancer patients. METHODS: Twenty patients with recurrent prostate cancer were enrolled. In 2 consecutive days, each patient underwent a 60-min dynamic PET/CT scan after intravenous administration of 148-185 MBq (4-5 mCi) [68 Ga]Ga-P16-093 and [68 Ga]Ga-PSMA-617, respectively. Following a low-dose CT scan, serial dynamic PET scans were performed from head to proximal thigh at 9 time points (30 s/bed at 4, 7, 10, 13, and 16 min; 1 min/bed at 20, 30, and 45 min; and 2 min/bed at 60 min). Standardized uptake values were measured for semi-quantitative comparison. RESULTS: [68 Ga]Ga-P16-093 PET/CT revealed a significantly higher tumor uptake at 4 min (SUVmax 7.88 ± 5.26 vs. 6.01 ± 3.88, P < 0.001), less blood pool retention at 4 min (SUVmean 5.12 ± 1.16 vs. 6.14 ± 0.98, P < 0.001), and lower bladder accumulation at 60 min (SUVmean 31.33 ± 27.47 vs. 48.74 ± 34.01, P = 0.042) than [68 Ga]Ga-PSMA-617 scan. Significantly higher [68 Ga]Ga-P16-093 uptakes were also observed in the parotid gland, liver, spleen, and kidney. Besides, [68 Ga]Ga-P16-093 exhibited a better detectability of tumor than [68 Ga]Ga-PSMA-617 (366 vs. 321, P = 0.009). CONCLUSIONS: [68 Ga]Ga-P16-093 showed advantages over [68 Ga]Ga-PSMA-617 with higher tumor uptakes, tumor-to-blood pool ratio and detection capability, less blood pool, and bladder accumulation in recurrent prostate cancer patients. TRIAL REGISTRATION: [68 Ga]Ga-P16-093 and [68 Ga]Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients (NCT04796467, Registered 12 March 2021, retrospectively registered) URL of registry: https://clinicaltrials.gov/ct2/show/NCT04796467.
引用
- Wang G, Hong H, Zang J, et al. Head-to-head comparison of [68 Ga]Ga-P16-093 and [68 Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients. Eur J Nucl Med Mol Imaging. 2021. PMID: 34557930. doi:10.1007/s00259-021-05539-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。